Status:

COMPLETED

Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients

Lead Sponsor:

Rhode Island Hospital

Conditions:

Actinic Keratoses

Eligibility:

All Genders

Phase:

EARLY_PHASE1

Brief Summary

Skin cancers and pre-cancerous growths (called actinic keratoses, "AKs"), that aren't melanomas, develop in patients with a kidney transplant at excessive rates. When these pre-cancerous AKs, and "non...

Detailed Description

Non-melanoma cutaneous carcinomas \[NMSCs\], predominantly squamous cell carcinomas \[SCCs\], as well as basal cell carcinomas \[BCCs\], are the most common malignancies occurring in kidney transplant...

Eligibility Criteria

Inclusion

  • Kidney transplant ≥ 12-months ago
  • ongoing, standard immunosuppression regimen
  • current CKD
  • EPI estimated (43)
  • glomerular filtration rate (eGFR) ≥ 15 ml/min per 1.73 m2)
  • Prior history of at least one NMSC

Exclusion

  • Kidney transplant \<12-months ago, treatment for acute rejection \<= 3-months ago, or current eGFR\< 20
  • Known history of active liver disease/ transaminitis \[alanine aminotransferase, ALT \> 1.5 X upper limit of normal\]
  • Serum phosphorus \< 2.0 mg/dL or average ≤ 100 × 10(9)/mL platelets
  • Internal malignancy, metastatic SCC, or invasive melanoma within the past 5-years
  • Overwhelming numbers of current skin cancers or large areas of confluent skin cancer at baseline preventing accurate assessment and counting of new skin cancers
  • Field treatment for AKs within the past 4-weeks, preventing accurate assessment of AKs
  • Patients begun on acitretin or other oral retinoids, or mTOR inhibitors within the past 6-months (If stably taking for more than six months, they may participate)
  • Gorlin's syndrome or other genetic skin cancer syndrome
  • Patients unavailable for follow-up for the duration of the study because of social/ geographical reasons, or general frailty
  • Pregnancy or lactation (all women of childbearing will be required to use contraception throughout the study)
  • Patients taking supplemental NAM within the past 4-weeks

Key Trial Info

Start Date :

October 14 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 18 2020

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04843553

Start Date

October 14 2016

End Date

December 18 2020

Last Update

April 22 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.